Pharmaceutical giant Mylan will pay US$750 million in cash, plus additional contingent payments of up to US$50 million, to private equity firm AIF Capital to acquire certain female reproductive health care businesses from Famy Care, the world’s largest producer of female oral contraceptives.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
